Omeros(US:OMER) The Motley Fool·2025-12-24 22:22Core Insights - Omeros has received FDA approval for its drug Yartemlea, marking a significant milestone for the company and leading to a nearly 76% increase in its stock price [1][2][6] Company Overview - Omeros is preparing for the launch of Yartemlea, which is the first FDA-approved treatment for thrombotic microangiopathy associated with hematopoietic stem cell transplants [2][5] - The company has established dedicated billing and reimbursement codes and plans to introduce the YARTEMLE Assist patient support program by early 2026 [5] Clinical Performance - In pivotal trials, Yartemlea demonstrated a 100-day survival rate of 73% for patients suffering from TA-TMA [4] Market Position - Omeros holds a first-mover advantage in the TA-TMA treatment market, which positions the company strongly against competitors [7] - The company has a diverse pipeline, indicating potential for future success with additional treatments [7]